-
Nepal's former energy minister arrested in graft probe
-
IOC reinstating gender tests 'a disrespect for women' - Semenya
-
High hopes at China's gateway to North Korea as trains resume
-
Antonelli wins in Japan to become youngest F1 championship leader
-
Mercedes' Antonelli wins Japanese Grand Prix to take lead
-
Germany's WWII munitions a toxic legacy on Baltic Sea floor
-
Iran claims aluminium plant attacks in Gulf as Houthis join war
-
North Korea's Kim oversees test of high-thrust engine: state media
-
Five Apple anecdotes as iPhone maker marks 50 years
-
'Excited' Buttler rejuvenated for IPL after horror T20 World Cup
-
Ship insurers juggle war risks for perilous Gulf route
-
Helplines buzz with alerts from seafarers trapped in war
-
Let's get physical: Singapore's seniors turn to parkour
-
Indian tile makers feel heat of Mideast war energy crunch
-
At 50, Apple confronts its next big challenge: AI
-
Houthis missile attacks on Israel widen Middle East war
-
Massive protests against Trump across US on 'No Kings' day
-
Struggling Force lament missed opportunities after Chiefs defeat
-
US thrashed 5-2 by Belgium in reality check for World Cup hosts
-
Lakers guard Doncic gets one-game ban for accumulated technicals
-
Houthis claim missile attacks on Israel, entering Middle East war
-
NBA Spurs stretch win streak to eight in rout of Bucks
-
US lose 5-2 to Belgium in rude awakening for World Cup hosts
-
Sabalenka sinks Gauff to win second straight Miami Open title
-
Lebanon kids struggle to keep up studies as war slams school doors shut
-
Cherry blossoms, kite-flying and 'No Kings' converge on Washington
-
Britain's Kerr to target El Guerrouj's mile world record
-
Sailboats carrying aid reach Cuba after going missing: AFP journalist
-
Pakistan to host Saudi, Turkey, Egypt for talks on Mideast war
-
Formidable Sinner faces Lehecka for second Miami Open title
-
Tuchel plays down Maguire's World Cup hopes
-
'Risky moment': Ukraine treads tightrope with Gulf arms deals
-
Japan strike late to win Scotland friendly
-
India great Ashwin joining San Francisco T20 franchise
-
Israel hits Iran naval research site, fresh blasts rattle Tehran
-
Kohli fires Bengaluru to big win after IPL remembers stampede dead
-
Graou shines as Toulouse sink Montpellier, Pau climb to second in Top 14
-
Vingegaard nears Tour of Catalonia victory with stage six win
-
Malinin bounces back from Olympic meltdown with third straight world skating gold
-
French police foil Paris bomb attack outside US bank
-
Senegal parade AFCON trophy at Stade de France, despite being stripped of title
-
Graou shines as Toulouse sink Montpellier to extend Top 14 lead
-
Anti-Trump protests launch on 'No Kings' day in US
-
Protesters rally in London against UK far-right rise
-
France foils Paris bomb attack outside US bank
-
Indian Premier League cricket season begins with silence to honour stampede dead
-
Missing Cuba-bound aid boats located, crew reported safe
-
Ignore our celebrations, we respect Bosnian team, says Italy's Dimarco
-
Case closed for Morocco despite Senegal Afcon outrage
-
22 migrants die off Greece after six days at sea: survivors
Drew Weissman, Nobel-winning mRNA pioneer
Drew Weissman's decades of research into mRNA technology paved the way for Covid-19 vaccines, finally earning a Nobel prize for the physician-scientist.
The 64-year-old University of Pennsylvania immunologist, who won the Nobel Medicine Prize along with long-time collaborator Katalin Kariko on Monday, is far from done.
His next quests include, among others, developing a vaccine against all future coronaviruses.
"There have been three (coronavirus) pandemics or epidemics in the past 20 years," Weissman told AFP recently, referring to the original SARS virus, MERS and Covid-19.
"You have to assume there's going to be more, and our idea was that we could wait for the next coronavirus epidemic or pandemic, and then spend a year and a half making a vaccine. Or we could make one now."
- Twin breakthroughs-
The world is now aware of the elegance of the mRNA (messenger ribonucleic acid) vaccines, that deliver genetic instructions to cells telling them to recreate the spike protein of the coronavirus, in order to trigger effective antibodies when they encounter the real thing.
But back when Weissman teamed up with Kariko in the 1990s, the research was considered a scientific dead-end, and working with DNA was considered a more promising avenue.
"We started working together in 1998, and that was without much funding and without much in the way of publications," he said.
In 2005, the pair found a way to alter synthetic RNA to stop it from causing a massive inflammatory response found in animal experiments.
"Just before our paper was published, I said 'Our phones are going to ring off the hook,'" he recalls.
"We sat there staring at our phones for five years, and they never rang!"
With a second big breakthrough in 2015, they found a new way to deliver the particles safely and effectively to their target cells, using a fatty coating called "lipid nanoparticles."
Both developments are part of the Pfizer and Moderna Covid-19 vaccines today.
- Helping people -
Weissman grew up in Lexington, Massachusetts.
His father and mother, both since retired, were an engineer and dental hygienist, respectively.
"When I was five years old, I was diagnosed as a type-one diabetic, and back then it was testing urine and taking insulin shots a few times a day," he recalled, and this motivated him to pursue science.
He was educated at Brandeis University and completed an MD-Phd program in immunology at Boston University.
As a young fellow at the National Institutes of Health, he worked for several years in Anthony Fauci's lab on HIV research, before finally arriving at his long-time home Penn.
Weissman was a practicing doctor until a few years ago, and says it brings him great joy that his invention has helped save millions of lives.
"I'm a clinician scientist, my dream since starting college and medical school was to make something that helps people. I think I can say that I've done that. So I am incredibly happy," he said.
Beyond vaccines, mRNA technology is also being heralded for its potential across medicine.
Weissman's team is working on using RNA to develop a single-injection gene therapy to overcome the defect that causes sickle cell anemia, a genetic blood disease that 200,000 babies are born with in Africa every year.
Significant technical challenges remain to ensure the treatment is able to correctly edit genes and is safe, but the researchers are hopeful.
Bone marrow transplant, an expensive treatment with serious risks, is currently the only cure.
O.Johnson--AMWN